Report
Martial Descoutures

Un réel changement de paradigme avec Primer Design - ACHAT, Oc 2,4€

Nous initions NOVACYT avec une recommandation à ACHAT et un objectif de 2,4€ (+79%). Avec l’acquisition de Primer Design, le groupe franchit un cap en termes de taille (CA 2016e de 13,9m€), de profitabilité (EBITDA 2016e proche de l'équilibre) et parviendrait à autofinancer son exploitation dès la fin 2017. NOVACYT dispose d’un portefeuille d’activités équilibré (cytologie, hématologie/sérologie, microbiologie et biologie moléculaire) avec de fortes perspectives de croissance (TMVA CA 2016-18e de +14%) sans intégrer encore les synergies attendues de l’acquisition,
Underlying
Novacyt SAS

Novacyt is an international diagnostics group. Co. sales clinical products used in oncology, microbiology, haematology and serology testing, focusing on the development, manufacture and commercialisation of molecular, protein and whole-cell diagnostic products. Co. also develops new products for the infectious disease and oncology testing markets. Co. operates it business through three divisions that are principally based in the United Kingdom with additional operations in France, China, Australia and the United States: Primerdesign, NOVAprep® and Lab21.

Provider
Invest Securities
Invest Securities

Since 2006, Invest Securities has become one of the leading players in investment services for funds and managers, to whom we offer a global and personalised service. Our track record differentiates us and proves our leadership in numerous promising sectors like property and growth companies.

Consisting of 13 different profiles (pharmacist, engineer, financier, etc), the DNA of our financial analysis office is value added and sector expertise. Through daily monitoring and detailed analyses of companies and sectors, we seek to provide a differentiating vision of our 120 stocks followed. Our ideas are circulated every day to nearly 1,000 professionals.

Analysts
Martial Descoutures

Other Reports on these Companies
Other Reports from Invest Securities
Bruno Duclos ... (+3)
  • Bruno Duclos
  • Eva Olejniczak
  • Stéphane Afonso
Bruno Duclos ... (+3)
  • Bruno Duclos
  • Eva Olejniczak
  • Stéphane Afonso

ResearchPool Subscriptions

Get the most out of your insights

Get in touch